China’s biopharma sector enters the New Year on a high
A wave of lucrative licensing deals, drug approvals and positive policy moves spurred a pharmaceutical rally in 2025, but bigger biotechs are seeing more of the benefits Key Takeaways: The…
BeiGene goes for global growth with sales and R&D push
The maker of cancer drugs is ploughing most of its rising revenues into research and sales, as it prioritizes expansion over profits for now Key Takeaways: BeiGene’s revenue in the…
Sihuan Pharma’s Botox Beauty Bid Suffers Covid Wrinkle
The cardiovascular and cancer drug maker’s recent shift to the medical beauty business was doing well at first, but struggled last yearKey Takeaways:Sihuan Pharmaceutical’s recent move into the medical beauty…
